Ustekinumab-stba

Drug Overview

Starjemza is a biosimilar immunomodulator to ustekinumab (Stelara) used to manage autoimmune inflammatory diseases. It is a monoclonal antibody that provides clinically equivalent safety, purity, and efficacy to the reference biologic.

It belongs to the interleukin inhibitor class and works by targeting cytokine signaling pathways that drive chronic inflammation.

As a targeted therapy, it helps restore immune balance, reduce disease activity, and offers a high-quality biosimilar alternative for long-term management of severe autoimmune conditions

• Generic Name: Ustekinumab-stba
• US Brand Name: Starjemza
• Drug Category: [Immunology]
• Drug Class: Interleukin Inhibitor (IL-12 and IL-23 antagonist)
• Route of Administration: Available as an initial intravenous (IV) infusion (for IBD induction) and a subcutaneous (SC) injection for maintenance.
• FDA Approval Status: FDA-approved (2024–2025) as a biosimilar for the treatment of multiple chronic inflammatory conditions.

What Is It and How Does It Work? (Mechanism of Action)

To understand how Starjemza functions as a Targeted Therapy, one must examine the cytokines—specialized proteins that coordinate the body’s immune response. In many autoimmune diseases, the body produces an excess of two specific cytokines: Interleukin-12 (IL-12) and Interleukin-23 (IL-23). These proteins act as the “on” switch for the inflammatory cells responsible for attacking healthy tissues in the skin, joints, and gastrointestinal tract.

At the molecular and cellular level, Starjemza exerts its effect through selective cytokine inhibition:

1. Targeting the p40 Subunit: Both IL-12 and IL-23 cytokines share a common protein component called the p40 subunit. Starjemza is a Monoclonal Antibody engineered to bind specifically and with high affinity to this p40 subunit.
2. Interruption of Receptor Binding: By binding to the p40 subunit, the drug prevents IL-12 and IL-23 from attaching to the IL-12Rβ1 receptor protein found on the surface of immune cells, such as T-cells and Natural Killer (NK) cells.
3. Suppression of Th1 and Th17 Pathways: This blockade effectively stops the activation and growth of Th1 and Th17 cells. Th1 cells drive the production of Interferon-gamma, while Th17 cells produce IL-17—both are key drivers of the systemic inflammation seen in Crohn’s disease and psoriasis.
4. Halting Intracellular Signaling: The prevention of receptor binding stops the downstream JAK-STAT signaling pathway interference within the immune cell. Without this signal, the “command” to create inflammation never reaches the cell’s nucleus.
5. Restoring Balance: Unlike older immunosuppressants that broadly weaken the immune system, this Targeted Therapy selectively calms the overactive pathways, allowing the patient to maintain essential defenses against most common infections.

FDA-Approved Clinical Indications

Starjemza is utilized as a powerful Immunomodulator across several key indications within the Immunology spectrum.

Primary Indication

• Starjemza (Ustekinumab biosimilar): Specifically indicated for the treatment of moderate-to-severe Plaque Psoriasis, active Psoriatic Arthritis, moderately to severely active Crohn’s Disease, and moderately to severely active Ulcerative Colitis.

Other Approved & Off-Label Uses

• Plaque Psoriasis (Ps): Approved for adult and pediatric patients (6 years and older) who are candidates for phototherapy or systemic therapy.
• Psoriatic Arthritis (PsA): Indicated for adult patients, used alone or in combination with methotrexate.
• Crohn’s Disease (CD): For adults who have failed or were intolerant to traditional therapies or TNF blockers.
• Ulcerative Colitis (UC): For adults to induce and maintain clinical remission and mucosal healing.
• Researching Off-Label Potential: While not officially approved for these, researchers are exploring the role of IL-12/23 inhibition in treating conditions like Ankylosing Spondylitis and certain forms of Lupus (SLE).

Primary Immunology Indications

• Cytokine Neutralization: Reducing the circulating p40 levels to prevent systemic “flare-ups” and organ damage.
• Mucosal Healing: Facilitating the repair of the intestinal wall in patients with inflammatory bowel disease.
• Dermal Regulation: Normalizing the life cycle of skin cells to eliminate the thick, scaly plaques of psoriasis.

Dosage and Administration Protocols

Dosing for Starjemza is highly personalized and often weight-based to ensure the Biologic reaches therapeutic levels in the bloodstream.

Protocol Adjustments and Special Populations:

• IBD Loading: For Crohn’s and UC, the first dose is a one-time IV infusion (260 mg for ≤55 kg, 390 mg for >55–85 kg, and 520 mg for >85 kg).
• Maintenance Transition: The first SC maintenance dose for IBD is administered 8 weeks after the initial IV infusion.
• Pediatric Patients: Dosing for children 6 years and older with psoriasis is strictly weight-based (0.75 mg/kg for those under 60 kg).
• Elderly: No specific dose adjustment is generally required, though vigilant monitoring for infection is essential in patients over 65.

Clinical Efficacy and Research Results

The clinical profile of Starjemza is supported by “totality of evidence” trials conducted between 2020 and 2026. Because it is a biosimilar, research has confirmed that switching from the reference product to Starjemza does not result in a loss of efficacy or an increase in side effects.

Current research highlights include:

• Skin Clearance (PASI): In trials for Plaque Psoriasis, approximately 67% to 75% of patients achieve a PASI 75 (75% improvement in skin coverage) within the first 12 weeks.
• Joint Relief (ACR): For Psoriatic Arthritis, precise numerical data shows ACR20 and ACR50 scores equivalent to the reference biologic, indicating significant reduction in joint pain and swelling.
• IBD Remission: Clinical studies confirm that over 50% of patients with Crohn’s or UC achieve clinical remission by the end of the induction phase.
• Inflammatory Markers: Data highlights a consistent reduction in C-Reactive Protein (CRP) and Erythrocyte Sedimentation Rate (ESR) levels, which are objective numerical markers of systemic inflammation.
• Sustainability: Real-world evidence from 2025–2026 suggests that the IL-12/23 pathway remains effective long-term, with a low incidence of “loss of response” due to anti-drug antibodies.

Safety Profile and Side Effects

As an Immunomodulator, Starjemza alters the immune response, requiring a clear understanding of its safety parameters.

• Black Box Warning: Starjemza does not have a Black Box Warning. However, it carries warnings for serious infections and malignancies.

Common Side Effects (>10%)

• Nasopharyngitis: Common cold-like symptoms, sore throat, and runny nose.
• Upper Respiratory Infections: Mild infections of the nose or throat.
• Headache and Fatigue: General sense of tiredness or mild head pain.
• Injection Site Reactions: Redness, swelling, or itching where the SC shot was given.

Serious Adverse Events

• Serious Infections: Increased risk of bacterial, fungal, or viral infections (including Tuberculosis reactivation).
• Malignancies: A theoretical risk of non-melanoma skin cancers.
• Posterior Reversible Encephalopathy Syndrome (PRES): A very rare neurological condition involving headache and visual changes.
• Non-Infectious Pneumonia: Rare instances of lung inflammation that require immediate medical attention.

Management Strategies

Clinical management involves a strict “screening protocol.” All patients must undergo a QuantiFERON-TB Gold test before starting. If an infection occurs, a “wash-out” period is implemented. “Pre-medication” with antihistamines is rarely needed but may be used for patients with a history of minor infusion reactions during the induction phase.

Research Areas

Direct Clinical Connections:

In the 2024–2026 research landscape, specialists are focusing on Starjemza’s interaction with regulatory T-cell (Treg) expansion. Researchers believe that by modulating the IL-12/23 pathway, they can encourage the body to produce more Tregs, which naturally help suppress autoantibody production and reduce cytokine storms.

Generalization:

The development of biosimilars like Starjemza is a core focus for international health brands to improve the sustainability of global health systems. Research is also moving toward “Novel Delivery Systems,” such as wearable on-body injectors and more concentrated subcutaneous formulas to reduce the volume of liquid injected, enhancing comfort for home use.

Severe Disease & Multi-Organ Involvement:

Precision Immunology research is evaluating the drug’s role in preventing systemic damage, such as lupus nephritis or interstitial lung disease, in patients who have failed other biologics. By using the drug earlier in the disease course, researchers hope to prevent permanent organ scarring in severe autoimmune cases.

Disclaimer:

This information should be treated as evidence-based but not definitive. Statements implying proven Treg expansion, reliable autoantibody suppression, established on-body injector use, confirmed cytokine-storm prevention, or guaranteed prevention of lupus nephritis and interstitial lung disease should be interpreted cautiously unless supported by direct clinical evidence. Starjemza is being positioned in a biosimilar IL-12/23 framework, but many broader precision-immunology and delivery-related claims remain investigational.

Patient Management and Clinical Protocols

Pre-treatment Assessment

• Baseline Diagnostics: QuantiFERON-TB Gold test for Tuberculosis and Hepatitis B/C screening.
• Organ Function: Complete Blood Count (CBC) and Liver Function Tests (LFTs).
• Specialized Testing: Baseline inflammatory markers (CRP/ESR) to monitor progress.
• Vaccination Screening: Patients should be up to date on all inactivated vaccines before starting a Targeted Therapy.

Monitoring and Precautions

• Vigilance: Monitoring for signs of infection (fever, chills, persistent cough) and periodic skin exams.
• Loss of Response: Physicians monitor for “anti-drug antibodies” if a patient stops responding to the medication.
• Lifestyle: We recommend an anti-inflammatory diet and sun protection to manage photosensitive conditions and reduce the risk of skin flares.

Do’s and Don’ts List:

• DO alert your doctor immediately if you develop a fever or a persistent cough.
• DO carry your Patient Safety Card with you at all times.
• DO stay hydrated and manage stress to support your immune system.
• DON’T receive any “live” vaccines (like shingles or MMR) while on this medication.
• DON’T skip scheduled blood work or monitoring appointments.

Legal Disclaimer

The medical information provided in this guide is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Starjemza is a potent Biologic and must only be used under the direct, continuous supervision of a licensed healthcare professional. Always seek the advice of your physician or a specialist immunologist regarding any medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this document. In the event of a medical emergency, contact your local emergency services immediately